Definitive Contract 75A50123C00034

Award Date 7/28/23
Potential Completion Date 5/31/25
Potential Value $749K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Tucson, AZ 85719, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>This is a $745,507.23 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Swaza Inc., a minority-owned, woman-owned small business, for research and development on the development of a breakthrough nanofluid breathing aid for the treatment of acute respiratory distress. The contract has a period of performance through June 28, 2025 and was awarded on June 29, 2023 with no set-aside designation.</p>
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $29,026,970.00 cost-plus-fixed-fee contract was awarded on September 9, 2019 to perform work under HHS-NIH-NIAID-BAA2018. The contract has an ultimate completion date of August 17, 2024 and does not have a set-aside designation....
This is a $190,241,861.21 Other Transaction Agreement awarded by the Department of the Army's Joint PEO Chemical and Biological Defense to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.), a technology-focused biomanufacturing company. The contract does not have a set-aside designation. The agreement, awarded on February 21, 2020, supports the development and manufacturing of medical countermeasures against biological threats and COVID-19. Resilience has provided...
This is a $239,992.00 Firm Fixed Price SBIR Phase I contract awarded by the Naval Air Warfare Center (NAWC) to Nanovox, LLC, a small business specializing in nanotechnology research and development. The contract is designated as a Total Small Business set-aside and will support advanced research and development related to the SBIR program, which focuses on innovative technological solutions for government challenges. Nanovox, a for-profit limited liability company and Subchapter S corporation,...
This is a $1,199,702.00 cost-plus-fixed-fee definitive contract awarded by the Naval Strategic Systems Programs (NAVSSP) division of the U.S. Navy to Nanovox, LLC, a small business specializing in nanotechnology research and development. The contract is part of the Small Business Innovation Research (SBIR) Program and is designated as a Phase II action, building upon prior SBIR work. The contract aims to support Nanovox's research and development of advanced materials and manufacturing...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Office of Naval Research (ONR) to Nanovox, LLC, a small business specializing in nanotechnology research and development. The $239,972 firm-fixed-price contract is for work under SBIR Topic N231-063, with a period of performance through July 16, 2024. As a total small business set-aside, this award reflects Nanovox's capabilities in advanced materials, optics, photonics, and metamaterials research to support...
This is a $1,759,916.97 cost-plus-fixed-fee contract awarded to Nanovox, LLC, a small business, by the Air Force Research Laboratory (AFRL) under the Small Business Innovation Research (SBIR) program. The contract is for the additive manufacturing of nanocomposite radiation shields and is set to be completed by April 30, 2026. Nanovox, LLC is a small business specializing in nanotechnology research, development, and commercialization, with a focus on optics, photonics, and metamaterials. The...
This is a $239,999.00 Small Business Technology Transfer (STTR) Phase I research and development contract awarded to Nanovox, LLC, a small business specializing in nanotechnology, optics, and metamaterials. The contract, designated as a total small business set-aside, was awarded by the Office of Naval Research (ONR) for the development of advanced materials and manufacturing technologies, including nanocomposite radiation shields, resistive films, wideband metamaterial RF antennas, and freeform...
This is a $1,099,988.88 firm fixed-price contract awarded by the U.S. Army's Research, Development and Engineering Command (DEVCOM) to Parabon NanoLabs, Inc., a small business, on July 11, 2022. The contract is for the development and demonstration of a novel, innovative nanoantibiotics platform to design and synthesize nanocarriers able to effectively deliver antimicrobial peptides to lung tissue to treat pulmonary infections from aerosolized biothreat agents. This contract is part of the...
This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...

This is a $749,447.48 definitive, firm-fixed price contract awarded to Nuvox Pharma, L.L.C., a small disadvantaged business, by the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. The contract is for research and development of a novel oxygen therapeutic nanotechnology (NANO2) for the treatment of COVID-19. It extends work from a previous award under Announcement of Opportunity #19. The contract has an ultimate completion date of May 31, 2025 and does not have a set-aside designation. Nuvox Pharma has also received federal grant awards from the NIH and Defense Health Agency to support the development of NANO2 for ischemic stroke and triple negative breast cancer.

Generated 5/3/25, 10:43 AM